In the context of COVID-19, Grifols' commitment to people's health and well-being begins with facilitating the early detection of infection. For this reason, and with the aim of increasing the rate of diagnosis using effective tests, Grifols has developed two types of tests to detect infection by SARS-CoV-2, the virus that causes COVID-19. This includes a molecular test, which detects the virus's RNA in respiratory and blood samples, as well as immunological tests that identify antibodies to the virus in serum, blood or plasma samples.

Molecular test to detect viral RNA

Molecular tests, due to their high sensitivity and specificity, are the most reliable tests for detecting the presence of SARS-CoV-2. They are based on PCR (polymerase chain reaction) technology or isothermal amplifications, such as TMA (transcription-mediated amplification). The molecular test developed by Grifols (TMA) detects the presence of the SARS-CoV-2 virus in respiratory, blood, serum or plasma samples.

Immunological tests for antibody detection

Grifols also offers two immunoassays based on ELISA technology to detect antibodies to the virus in blood, serum or plasma samples, and also provides a rapid antibody test using lateral flow technology. These tests play a fundamental role in epidemiology studies, immunity evaluations and vaccination programs.


For more information on Grifols' molecular test for SARS-CoV-2 and immunological tests that identify antibodies, visit SARS CoV-2 Testing.